What's new? Log in Free sign up

Psyence Biomedical (PBM)

Company Profile

Company profile

Ticker

PBM, PBMWW

Exchange

Website

www.psyencebiomed.com

CEO

Dr. Neil Maresky M.D.

Incorporated

Ontario, Canada

Location

Ontario, Canada

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

WORK Medical Technology LTD

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

PBM stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Registration statement (foreign)

Current report (foreign)

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Current report (foreign)

Current report (foreign)

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Current report (foreign)

Notice of effectiveness

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

Registration statement (foreign)

Latest ownership filings

White Lion Capital LLC

Harraden Circle Investments, LLC

Harraden Circle Investments, LLC

Harraden Circle Investments, LLC

Harraden Circle Investments, LLC

AdvisorShares Trust

Psyence Group Inc.

Harraden Circle Investments, LLC

Financial summary

Financial statements Chart PBM financial data

Quarter (USD)	Mar 24	Jan 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 24	Jan 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

PBM institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	26	28	-7.1%
Opened positions	2	1	+100.0%
Closed positions	4	3	+33.3%
Increased positions	2	2	–
Reduced positions	1	1	–

13F shares	Current	Prev Q	Change
Total value	74.07 mm	69.76 mm	+6.2%
Total shares	10.87 mm	6.58 mm	+65.2%
Total puts	0.00	0.00
Total calls	308.00 k	108.00 k	+185.2%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Harraden Circle Investments	3.35 mm	$315.00 k	NEW
MSOS AdvisorShares Pure US Cannabis ETF	1.23 mm	$116.00 k	NEW
Cowen And	1.22 mm	$15.38 mm	+4.4%
Polar Asset Management Partners	733.00 k	$9.24 mm	0.0%
MMCAP International Inc. SPC	600.00 k	$7.56 mm	0.0%
Calamos Advisors	500.00 k	$6.35 mm	0.0%
Cantor Fitzgerald, L. P.	468.50 k	$5.90 mm	0.0%
Saba Capital Management	297.85 k	$3.75 mm	0.0%
Clear Street Derivatives	277.92 k	$4.00 k	0.0%
Aristeia Capital	272.86 k	$3.10 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Harraden Circle Investments	3.35 mm	+3.35 mm	NEW
MSOS AdvisorShares Pure US Cannabis ETF	1.23 mm	+1.23 mm	NEW
LMR Partners	0.00	-200.00 k	EXIT
Flow State Investments	0.00	-55.00 k	EXIT
Cowen And	1.22 mm	+51.78 k	+4.4%
Whitebox Advisors	0.00	-50.00 k	EXIT
Shaolin Capital Management	148.81 k	-26.19 k	-15.0%
SkyView Investment Advisors	0.00	-17.50 k	EXIT
Clear Street	180.43 k	+150.00	+0.1%
UBS UBS	0.00	-73.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Psyence Biomed Announces $2M Private Placement

Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded

Psyence Biomed Regains Nasdaq Compliance After Share Consolidation

Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq

12 Health Care Stocks Moving In Friday's Pre-Market Session

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'

Press releases

From Benzinga Pro

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that the Company has

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), has been engaged to

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has progressed beyond the previously-announced non-binding

"Power Nickel (TSX.V: PNPN) (OTCQB: PNPNF) Announces Dividend – MIGI, PRFX, PBM, CSDX Stocks Trending Now!"

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.